Production and comprehensive quality control of recombinant human Interleukin-1β: A case study for a process development strategy

Protein Expression and Purification

Volumn 57, Issue 2, 2008, Pages 244-254

  Block, Helena ^a   Kubicek, Jan ^a   Labahn, Jörg ^b   Roth, Udo ^a   Schäfer, Frank ^a  

^a QIAGEN GMBH   (Germany)

^b FORSCHUNGSZENTRUM JÜLICH   (Germany)

Author keywords

DAPase; Expression screening; His tag cleavage; Immobilized Metal Affinity Chromatography (IMAC); Interleukin 1 (IL 1 ); Ni NTA; Protein production; TAGZyme; X ray crystallography

Indexed keywords

DEOXYRIBONUCLEASE; ENDOTOXIN; EXOPEPTIDASE; HIS HIS HIS HIS HIS HIS; HIS-HIS-HIS-HIS-HIS-HIS; HISTIDINE; INTERLEUKIN 1BETA; OLIGOPEPTIDE; RECOMBINANT PROTEIN; RIBONUCLEASE; SERRATIA MARCESCENS NUCLEASE; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; AMINO ACID SEQUENCE; ARTICLE; BIOSYNTHESIS; BIOTECHNOLOGY; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; SEQUENCE ANALYSIS; TWO DIMENSIONAL GEL ELECTROPHORESIS;

AMINO ACID SEQUENCE; BIOTECHNOLOGY; CHROMATOGRAPHY, AFFINITY; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENDODEOXYRIBONUCLEASES; ENDORIBONUCLEASES; ENDOTOXINS; EXOPEPTIDASES; HISTIDINE; HUMANS; INTERLEUKIN-1BETA; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; RECOMBINANT PROTEINS; SEQUENCE ANALYSIS, PROTEIN;

EID: 37349073090     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2007.09.019     Document Type: Article

References (64)

1. Champion K., Madden H., Dougherty J., and Shacter E. Defining your product profile and maintaining control over it, Part 2, challenges of monitoring host cell protein impurities. BioProcess Int. (2005) 52-57
2. Hoffman K. Strategies for host cell protein analysis. Biopharm 13 (2000) 38-45
3. Hartung T., Aaberge I., Berthold S., Carlin G., Charton E., Coecke S., Fennrich S., Fischer M., Gommer M., Halder M., Haslov K., Jahnke M., Montag-Lessing T., Poole S., Schechtmann L., Wendel A., and Werner-Felmayer G. Novel pyrogen tests based on the human fever reaction. Alternat. Labor. Animals 29 (2001) 99-123
4. C. Lauritzen, G. Petersen, J. Pedersen, J. Arnau, U. Römer, F. Schäfer, Reliable, large-scale cleavage of tags from affinity-purified biopharmaceuticals, in: J. Knäblein, (Ed.), Modern Biopharmaceuticals-Recent success stories, Wiley-VCH, Weinheim, in press.
5. McPherson A. A bit of advice on crystallizing proteins. In: Bergfors T.M. (Ed). Protein Crystallization-Techniques, Strategies, and Tips (1999), International University Line, Biotechnology Series, La Jolla 3-6
6. Derewenda Z.S. The use of recombinant methods and molecular engineering in protein crystallization. Methods 34 (2004) 354-363
7. Biocompare, protein chromatography: tools for protein expression and purification, Biocompare Suveys and Reports, Biocompare Inc., July 10, 2006.
8. Jenny R.J., Mann K.G., and Lundblad R.L. A critical review of the methods for cleavage of fusion proteins with thrombin and factor Xa. Protein Expr. Purif. 31 (2003) 1-11
9. Arnau J., Lauritzen C., Petersen G.E., and Pedersen J. Current strategies for the use of affinity tags and tag removal for the purification of recombinant proteins. Protein Expr. Purif. 48 (2006) 1-13
10. Pedersen J., Lauritzen C., Thorup M.M., and Weis D.S. Removal of N-terminal polyhistidine tags from recombinant proteins using engineered aminopeptidases. Protein Expr. Purif. 15 (1999) 389-400
11. Schäfer F., Schäfer A., and Steinert K. A highly specific system for efficient enzymatic removal of tags from recombinant proteins. J. Biomolec. Techniques 13 (2002) 158-171
12. Lauritzen C., Pedersen J., Madsen M.T., Justesen J., Martensen P.M., and Dahl S.W. Active recombinant rat dipeptidyl aminopeptidase I (cathepsin C) produced using the baculovirus expression system. Protein Expr. Purif. 14 (1998) 434-442
13. Dinarello C.A. Interleukin-1. Cytokine Growth Factor Rev. 8 (1997) 253-265
14. Veltri S., and Smith II J.W. Interleukin 1 trials in cancer patients: a review of the toxicity, antitumor and hematopoietic effects. Stem Cells 14 (1996) 164-176
15. Finzel B.C., Clancy L.L., Holland D.R., Muchmore S.W., Watenpaugh K.D., and Einspahr H.M. Crystal structure of recombinant human Interleukin-1β at 2.0 Å resolution. J. Mol. Biol. 209 (1989) 779-791
16. Bomford R. Will adjuvants be needed for vaccines in the future?. Dev. Biol. Stand. 92 (1998) 13-17
17. Buonocore F., Mazzini M., Forlenza M., Randelli E., Secombes C.J., Zou J., and Scapigliatti G. Expression in Escherichia coli and purification of sea bass (Dicentrarchus labrax) Interleukin 1β, a possible immunoadjuvant in aquaculture. Mar. Biotechnol. 6 (2004) 53-59
18. Bradney C.P., Sempowski G.D., Liao H.-X., Haynes B.F., and Staats H.F. Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. J. Virol. 76 (2002) 517-524
19. Staats H.F., and Ennis Jr. F.A. IL-1 is an effective adjuvant for mucosal and systemic immune response when coadministered with protein immunogens. J. Immunol. 162 (1999) 6141-6147
20. Ahlers J.D., Dunlop N., Alling D.W., Nara P.L., and Berzofsky J.A. Cytokine-in-adjuvant steering of the immune response phenotype to Hiv-1 vaccine constructs - granulocyte-macrophage colony stimulating factor and Tnf-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. J. Immunol. 158 (1997) 3947-3958
21. Murphy J.-E., Morales R.E., Scott J., and Kupper T.S. IL-1α, innate immunity, and skin carcinogenesis: the effect of consitutive expression of IL-1α in epidermis on chemical carcinogenesis. J. Immunol. 170 (2003) 5697-5703
22. Christ O., Matzku S., Burger C., and Zöller M. Interleukin 2-antibody and Tumor Necrosis Factor-antibody fusion proteins induce different antitumor immune responses in vivo. Clin. Cancer Res. 7 (2001) 1385-1397
23. Collaborative Computational Project, Number 4, The CCP suite: Programs for protein crystallography, Acta Cryst. D 50 (1994) 760-763.
24. Schaefer H., Chamrad D.C., Herrmann M., Stuwe J., Becker G., Klose J., Blueggel M., Meyer H.E., and Marcus K. Study of posttranslational modificatios in lenticular α-A-crystallin of mice using proteomic analysis techniques. Biochim. Biophys. Acta 1764 (2006) 1948-1962
25. Supplementary materials online (crystal picture, diffraction data, table with comprehensive IL-1β strutural data).
26. Rajan S.S., Lackland H., Stein S., and Denhardt D.T. Presence of an N-terminal polyhistidine tag facilitates stable expression of an otherwise unstable N-terminal domain of mouse tissue inhibitor of metalloproteinase-1 in Escherichia coli. Protein Expr. Purif. 13 (1998) 67-72
27. Sun Q.-M., Chen L.-L., Cao L., Fang L., Chen C., and Hua Z.-C. An improved strategy for high-level production of human vasostatin120-180. Biotechnol. Prog. 21 (2005) 1048-1052
28. Tang W., Sun Z.-Y., Pannell R., Gurewich V., and Liu J.-N. An efficient system for production of recombinant urokinase-type plasminogen activator. Protein Expr. Purif. 11 (1997) 279-283
29. Svensson J., Andersson C., Reseland J.E., Lyngstadaas P., and Bulow L. Histidine tag fusion increases expression levels of active recombinant amelogenin in Escherichia coli. Protein Expr. Purif. 48 (2006) 134-141
30. Cébe R., and Geiser M. Rapid and easy thermodynamic optimization of the 5́end of mRNA dramatically increases the level of wild type protein expression in Escherichia coli. Protein Expr. Purif. 45 (2006) 374-380
31. Flick K., Ahuja S., Chene A., Bejarano MT., and Chen Q. Optimized expression of Plasmodium falciparum erythrocyte membrane protein I domains in Escherichia coli. Malaria J. 3 (2004) 50
32. Jana S., and Deb J.K. Strategies for efficient production of heterologous proteins in Escherichia coli. Appl. Microbiol. Biotechnol. 67 (2005) 289-298
33. Studier F.W. Protein production by auto-induction in high-density shaking cultures. Protein Expr. Purif. 41 (2005) 207-234
34. Tang J., Hernandez G., and LeMaster D.M. Increased peptide deformylase activity for N -formylmethionine processing of proteins overexpressed in Escherichia coli: application to homogenous rubredoxin production. Protein Expr. Purif. 36 (2004) 100-105
35. DeJong J., and Roeder R.G. A single cDNA, hTFIIA/α, encodes both the p35 and p19 subunits of human TFIIA. Genes Dev. 7 (1993) 2220-2234
36. Ma D., Watanabe H., Mermelstein F., Admon A., Oguri K., Sun X., Wada T., Imai T., Shiroya T., Reinberg D., and Handa H. Isolation of a cDNA encoding the largest subunit of TFIIA reveals functions important for activated transcription. Genes Dev. 7 (1993) 2246-2257
37. Bolanos-Garcia V.M., and Davies O.R. Structural analysis and classification of native proteins from E. coli commonly co-purified by immobilised metal affinity chromatography. Biochim. Biophys. Acta 1760 (2006) 1304-1313
38. Mateo C., Fernandez-Lorente G., Pessela B.C.C., Vian A., Carrascosa A.V., Garcia J.L., Fernandez-Lafuente R., and Guisan J.M. Affinity chromatography of polyhistidine tagged enzymes: New dextran-coated immobilized metal ion affinity chromatography matrices for prevention of undesired multipoint adsorptions. J. Chromatog. A 915 (2001) 97-106
39. Saklatvala J., Curry V.A., and Sarsfield S.J. Purification to homogeneity of pig leucocyte catabolin, a protein that causes cartilage resorption in vitro. Biochem. J. 215 (1983) 385-392
40. Meyers C.A., Johanson K.O., Miles L.M., McDevitt P.J., Simon P.L., Webb R.L., Chen M.-J., Holskin B.P., Lillquist J.S., and Young P.R. Purification and characterization of human recombinant Interleukin-1β. J. Biol. Chem. 262 (1987) 11176-11181
41. Yem A.W., Richard K.A., Staite N.D., and Deibel Jr. M.R. Resolution and biological properties of three N-terminal analogues of recombinant Interleukin-1β. Lymphokine Res. 7 (1988) 85-92
42. Richard K.A., Yem A.W., Deibel Jr. M.R., and Staite N.D. Isolation and bioactivities of three IL-1β N-terminal variants. Agents Actions 27 (1989) 268-270
43. Covalt J.C., Cao T.B., Magdaroag J.R.C., Gross L.A., and Jennings P.A. Temperature, media, and point of induction affect the N-terminal processing of interleukin-1β. Prot. Expr. Purif. 41 (2005) 45-52
44. Carter D.B., Carter D.B., Curry K.A., Tomich C.-S.C., Yem A.W., Deibel M.R., Tracey D.E., Paslay J.W., Carter J.B., Theriault N.Y., Harris P.K.W., Reardon I.M., Zurcher-Neely H.A., Heinrikson R.L., Clancy L.L., Muchmore S.W., Watenpaugh K.D., and Einspahr H.M. Crystallization of recombinant human interleukin-1β. Prot. Struc. Func. Gen. 3 (1988) 121-129
45. Kirkpatrick R.B., Grooms M., Wang F., Fenderson H., Feild J., Pratta M.A., Volker C., Scott G., and Johanson K. Bacterial production of biologically active canine interleukin-1β by seamless SUMO tagging and removal. Prot. Expr. Purif. 50 (2006) 102-110
46. Kaslow D.C., and Shiloach J. Production, purification and immunogenicity of a malaria-blocking vaccine candidate: TBV25H expressed in yeast and purified using Ni-NTA agarose. Biotechnology 12 (1994) 494-499
47. Schäfer F., Blümer J., Römer U., and Steinert K. Ni-NTA for large-scale processes-systematic investigation of separation characteristics, storage and CIP conditions, and leaching. QIAGEN, QIAGEN News 4 (2000) 11-15
48. Hochuli E., Bannwarth W., Döbeli H., Gentz R., and Stüber D. Genetic approach to facilitate purification of recombinant proteins with a novel chelate adsorbent. Biotechnology 6 (1988) 1321-1325
49. Sun X., Chiu J.-F., and He Q.-Y. Application of immobilized metal affinity chromatography in proteomics. Expert Rev. Proteomics 2 (2005) 649-657
50. + antiporter as well as the growth phenotype of Escherichia coli. J. Biol. Chem. 273 (1998) 26470-26476
51. Franken K.L.M., Hiemstra H.S., van Meijgaarden K.E., Subronto Y., den Hartigh J., Ottenhoff T.H.M., and Drijfthout J.W. Purification of His-tagged protein by Immobilized Chelate Affinity Chromatography: the benefits from the use of organic solvents. Prot. Expr. Purif. 18 (2000) 95-99
52. Aida Y., and Pabst M.J. Removal of endotoxion from protein solutions by phase separation using Triton X-114. J. Immunol. Methods 132 (1990) 191-195
53. Reichelt P., Schwarz C., and Donzeau M. Single step protocol to purify recombinant proteins with low endotoxin contents. Protein Expr. Purif. 46 (2006) 483-488
54. Du Z., Lee J.K., Tjhen R., Li S., Pan H., Stroud R., and James T.L. Crystal structure of the first KH domain of human poly(C)-binding protein-2 in complex with a C-rich strand of human telomeric DNA at 1.7 Å. J. Biol. Chem. 280 (2005) 28823-38830
55. Kenig M., Peternel S., Gaberc-Porekar V., and Menart V. Influence of the protein oligomericity on final yield after affinity tag removal in purification of recombinant proteins. J. Chromatogr. A 1101 (2006) 293-306
56. Warren W.C., Bentle K.A., Schittler M.R., Schwane A.C., O'Neil J.P., and Bogosian G. Increased production of peptide deformylase eliminates retention of formylmethionine in bovine somatotropin overproduced in Escherichia coli. Gene 194 (1996) 235-238
57. Giglione C., Boularot A., and Meinnel T. Protein N-terminal methionine excision. Cell. Mol. Life Sci. 61 (2004) 1455-1474
58. Shimada Y., Wang Z.-Y., Mochizuki Y., Kobayashi M., and Nozawa T. Functional expression and characterization of a bacterial light-harvesting membrane protein in Escherichia coli and cell-free synthesis systems. Biosci. Biotechnol. Biochem. 68 (2004) 1942-1948
59. Yu B., Blaber M., Gronenburg A.M., Clore G.M., and Caspar D.L.D. Disordered water within a hydrophobic protein cavity visualized by X-ray crystallography. Proc. Natl. Acad. Sci. USA 96 (1999) 103-108
60. Shaanan B., Gronenburg A.M., Cohen G.H., Gilliland G.L., Veerapandian B., Davies D.R., and Clore G.M. Combining experimental information from crystal and solution studies. Sience 257 (1992) 961-964
61. Einspahr H., Clancy L.L., Muchmore S.W., Watenpaugh K.D., Harris P.K.W., Carter D.B., Curry K.A., Tomich C.-S.C., Yem A.W., Deibel M.R., Tracey D.E., Paslay J.W., Staite N.D., Carter J.B., Theriault N.Y., Reardon I.M., Zurcher-Neely H.A., and Heinrikson R.L. Crystallization of recombinant human Interleukin 1β. J. Crystal Growth 90 (1988) 180-187
62. R.A. Young, Toxicity summary for nickel and nickel compounds, In: Risk assessment information systems-toxicity profiles, The Health and Sciences Research Division, Oak Ridge National Laboratories, Oak Ridge, Tennessee (1995), Available from: http://risk.lsd.ornl.gov/tox/profiles/nickel_and_nickel_compounds_c_V1.shtml.
63. Food and Drug Administration, FDA, Guidance document for nickel in shellfish, Center for Food Safety and Applied Nutrition, CFSAN (1993), Available from: http://www.cfsan.fda.gov/∼frf/guid-ni.html.
64. Food and Drug Administration, FDA, Total diet study, Center for Food Safety and Applied Nutrition, CFSAN (2007), Available from: http://www.cfsan.fda.gov/∼comm/tds-toc.html.